Services > Probe Development

Probe Development

The next generation of drugs to be developed are those which take into account the subtle genetic and proteomic differences of each patient. This approach holds great promise for the treatment of tumours, depression and cardiac disease. Molecular imaging complements this approach in that it allows for the non-invasive assessment of biological pathways and biochemical processes in living subjects. This technology has the potential to advance our understanding of disease and the effect of new therapies and to select candidates for clinical trials that have a high probability of success. Alternatively, molecular imaging with probes can also be used to halt the development of new drugs that seem likely to fail, thereby helping to reduce the cost of drug discovery, which is expected to top $1.9B by 2013 [1].

At the CPDC we work with clients to develop imaging probes to facilitate early disease detection or so that imaging can be incorporated into trials. Our diverse experience in multiple modalities and the capability to perform onsite biodistribution, preclinical and clinical studies provide a one stop location for all probe development and molecular imaging needs.

Please contact us for more information »

[1] Willmann et al, Nature Reviews: Drug Discovery, Volume 7, July 2008, p591.